Athena Athena

X
[{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Daewoong Pharmaceutical","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"AEON Biopharma Announces FDA Acceptance of IND for ABP-450 as a Treatment for Cervical Dystonia; Secures $25 Million Investment","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"September 2020","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling"},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AEON Biopharma Initiates Enrollment in Phase 2 Trial of ABP-450 for the Preventive Treatment of Migraine","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"March 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II"},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AEON Biopharma Doses First Patient in Phase 2 Trial of ABP-450 for the Treatment of Cervical Dystonia","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"April 2021","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling"},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AEON Biopharma Completes Enrollment in Phase 2 Clinical Study of ABP-450 in Cervical Dystonia","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"April 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II"},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"AEON Biopharma Raises $30 Million From Insiders","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"August 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II"},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AEON Biopharma Reports Positive Topline Results from Phase 2 Clinical Trial of ABP-450 (prabotulinumtoxinA) in Cervical Dystonia","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"September 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II"},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Priveterra Acquisition Corp.","pharmaFlowCategory":"D","amount":"$475.5 million","upfrontCash":"$276.0 million","newsHeadline":"AEON Biopharma to Become Publicly Listed via Merger with Priveterra Acquisition Corp.; Accelerating Clinical Development of ABP-450 (prabotulinumtoxinA) Injection to Treat Debilitating Medical Conditions in Neurology","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"December 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II"},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AEON Biopharma Completes Enrollment in Phase 2 Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"December 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II"},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"AEON Biopharma and Priveterra Acquisition Corp. Announce Additional Capital Commitment from Existing Investors for at Least $20 Million","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"January 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II"},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AEON Biopharma Confirms Development Strategy and Timelines for ABP-450 Unaffected by Korean Court Ruling on Dispute Between Medytox and Daewoong Pharmaceutical","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"February 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II"},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$125.0 million","upfrontCash":"Undisclosed","newsHeadline":"AEON Biopharma and Priveterra Announce Arrangement of Up to $125 Million of Financing in Connection with Proposed Business Combination","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"June 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II"},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Priveterra Acquisition Corp.","pharmaFlowCategory":"D","amount":"$276.0 million","upfrontCash":"$276.0 million","newsHeadline":"Priveterra Acquisition Corp. Announces Intention to Transfer to NYSE upon Completion of Business Combination with AEON Biopharma, Inc.","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"July 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II"},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Priveterra Acquisition Corp.","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Priveterra Acquisition Corp. Announces Completion of Business Combination with AEON Biopharma, Inc.","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"July 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II"},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AEON Biopharma Announces Topline Results from Phase 2 Trial of ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Episodic Migraine","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"October 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II"},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AEON Biopharma Announces Clinical Update and Productive End-of-Phase 2 Meeting with FDA on ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Migraine","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II"},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Daewoong Pharmaceutical","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"AEON Biopharma Announces $15 Million Financing Transaction and Termination of Forward Purchase Agreements","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"March 2024","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II"}]

Find Clinical Drug Pipeline Developments & Deals by AEON Biopharma

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            ABP-450 (prabotulinumtoxinA) contains a 900 kDa botulinum toxin type-A complex produced by the bacterium Clostridium botulinum. It is being evaluated for the treatment of episodic and chronic migraine.

            Lead Product(s): PrabotulinumtoxinA

            Therapeutic Area: Neurology Product Name: ABP-450

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 19, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The proceeds will be used to support the late-stage clinical development of ABP-450, which contains a 900 kDa botulinum toxin type-A complex produced by the bacterium Clostridium botulinum, being developed for the treatment of episodic migraine.

            Lead Product(s): PrabotulinumtoxinA

            Therapeutic Area: Neurology Product Name: ABP-450

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Daewoong Pharmaceutical

            Deal Size: $15.0 million Upfront Cash: Undisclosed

            Deal Type: Private Placement March 19, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            ABP-450 (prabotulinumtoxinA) contains a 900 kDa botulinum toxin type-A complex produced by the bacterium Clostridium botulinum. AEON recently completed Phase 2 of ABP-450 for cervical dystonia and has an ongoing Phase 2 of ABP-450 for both chronic and episodic migraine.

            Lead Product(s): PrabotulinumtoxinA

            Therapeutic Area: Neurology Product Name: ABP-450

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 19, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The combined company will focus on the development of ABP-450 (prabotulinumtoxinA) injection, the same botulinum toxin approved and marketed for an aesthetic indication, to treat debilitating medical conditions in neurology.

            Lead Product(s): PrabotulinumtoxinA

            Therapeutic Area: Neurology Product Name: ABP-450

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Priveterra Acquisition Corp.

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Merger July 21, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The combined company will focus on the development of ABP-450 (prabotulinumtoxinA) injection, the same botulinum toxin approved and marketed for an aesthetic indication, to treat debilitating medical conditions in neurology.

            Lead Product(s): PrabotulinumtoxinA

            Therapeutic Area: Neurology Product Name: ABP-450

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Priveterra Acquisition Corp.

            Deal Size: $276.0 million Upfront Cash: $276.0 million

            Deal Type: Merger July 11, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The net funding will be used in the development of ABP-450 (prabotulinumtoxinA) which contains a 900 kDa botulinum toxin type-A complex produced by the bacterium Clostridium botulinum, for the preventive treatment of episodic migraine.

            Lead Product(s): PrabotulinumtoxinA

            Therapeutic Area: Neurology Product Name: ABP-450

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Undisclosed

            Deal Size: $125.0 million Upfront Cash: Undisclosed

            Deal Type: Financing June 30, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            ABP-450 (prabotulinumtoxinA) blocks peripheral acetylcholine release at presynaptic cholinergic nerve terminals by cleaving SNAP-25, a protein integral to the successful docking and release of acetylcholine thereby leading to denervation of the muscle and a flaccid paralysis.

            Lead Product(s): PrabotulinumtoxinA

            Therapeutic Area: Neurology Product Name: ABP-450

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 10, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            ABP-450 (prabotulinumtoxinA) contains a 900 kDa botulinum toxin type-A complex produced by the bacterium Clostridium botulinum. AEON recently completed Phase 2 of ABP-450 for cervical dystonia and has an ongoing Phase 2 of ABP-450 for both chronic and episodic migraine.

            Lead Product(s): PrabotulinumtoxinA

            Therapeutic Area: Neurology Product Name: ABP-450

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Undisclosed

            Deal Size: $20.0 million Upfront Cash: Undisclosed

            Deal Type: Financing January 10, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            ABP-450 contains a 900 kDa botulinum toxin type-A complex produced by the bacterium Clostridium botulinum. The active part of the botulinum toxin is the 150 kDa component, and the remaining 750 kDa of the complex is made up of accessory proteins.

            Lead Product(s): PrabotulinumtoxinA

            Therapeutic Area: Neurology Product Name: ABP-450

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 21, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            ABP-450 (prabotulinumtoxinA) is safe and effective for treating cervical dystonia, compared with placebo. ABP-450 (prabotulinumtoxinA) is a toxin produced by Clostridium botulinum.

            Lead Product(s): PrabotulinumtoxinA

            Therapeutic Area: Neurology Product Name: ABP-450

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Priveterra Acquisition Corp.

            Deal Size: $475.5 million Upfront Cash: $276.0 million

            Deal Type: Merger December 13, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY